The AI engine uncovering novel medicines that matter
Faster, better, and at scale for patients who are waiting
LEARN HOW
A portfolio of differentiated investigational medicines built on our AI drug discovery and development platform
Our wholly owned pipeline reflects a broad and diverse collection of potential new medicines in areas with high unmet need, including oncology and rare disease. For each program, the differentiation is driven by our AI-enabled product engine – from novel biology to precision design to clinical development.
Leading the evolution of AI drug discovery and development
Recursion is building a new way to discover and develop medicines at the intersection of science and technology. Our teams blend the humility and expertise of seasoned drug hunters with the ambition and vision of tech disrupters.
Inside the loop:
Learn how we map disease biology, design potential medicines, and progress them to the clinic — at scale
Take a look inside our automated labs to see how our AI-enabled, end-to-end drug discovery and development engine works as one system, tightly connecting biology, precision design, and translational clinical tools to systematically de-risk drug discovery. Learn how our wet and dry "lab-in-the-loop," forms a continuous learning system of physical automation and machine learning models, driven by global bilingual teams of scientists and technologists.
Explore our technologyConsistently delivering for our partners
We’re advancing joint portfolios with our pharma partners across some of the most complex disease areas. We apply our AI-native product engine to overcome specific therapeutic challenges – from identifying novel disease targets to precision designing molecules against historically challenging targets — with a strong track record of delivering “AI-firsts” for our partners.
10+
$500M+
.png)
Stay in touch with the latest from Recursion
Follow us on social media
.svg){kind=small}
.svg){kind=small}
.svg){kind=small}
"This is only possible because we control the design, make, and test steps within one connected system rather than handing off between disconnected tools and teams."
Read more →Recursion Announces Clinical Progress Across Two First-in-Class Programs, Sanofi Partnership Milestone, and $200 Million Public Offering
Read more →"Our integrated system narrows millions of molecules down to a short list that's synthetically accessible. Not just promising in silico, but actually makeable before a single one is sent to the labs."
Read more →
